Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.28% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Sep 30, 2023
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-23-000023General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
47.89% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
183.96% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
12.76% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
89.41% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
28.50% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
33.73% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
8.52% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 4.99%
- Current
- 2.28%
- Delta
- -2.72%
- Previous
- -18.51%
- Current
- 47.89%
- Delta
- 66.39%
- Previous
- 41.78%
- Current
- 183.96%
- Delta
- 142.18%
- Previous
- 31.51%
- Current
- 12.76%
- Delta
- -18.75%
- Previous
- 76.37%
- Current
- 89.41%
- Delta
- 13.05%
- Previous
- -72.10%
- Current
- 28.50%
- Delta
- 100.60%
- Previous
- 77.97%
- Current
- 33.73%
- Delta
- -44.23%
- Previous
- 23.78%
- Current
- 8.52%
- Delta
- -15.26%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_INCREASED →Transitioned To · ALNY GROWTH_INCREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_INCREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.